021-51111890
购物车（）
sales@molnova.cn
Droxicainide
CAS No. 78289-26-6
Droxicainide ( —— )
产品货号. M26178 CAS No. 78289-26-6
屈西卡尼 (Droxicainide) 是一种抗心律失常药。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥4034 | 有现货 |
|
| 10MG | ￥5873 | 有现货 |
|
| 25MG | ￥9153 | 有现货 |
|
| 50MG | ￥12312 | 有现货 |
|
| 100MG | ￥16038 | 有现货 |
|
| 500MG | ￥32157 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Droxicainide
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述屈西卡尼 (Droxicainide) 是一种抗心律失常药。
-
产品描述Droxicainide is an antiarrhythmic agent.(In Vivo):In coronary artery occlusion studies, Droxicainide reduced the progression of hypoperfusion to necrosis and reduced the infarct size in dogs.Droxicainide reduces ansa node, atrioventricular excitability and contractility, and increases intractable studies on spontaneous beating atrium, electrical stimulation atrium and isolated papillary muscles in rats.
-
体外实验——
-
体内实验In coronary artery occlusion study, Droxicainide reduces hypoperfused area that evolves to necrosis, and reduces the infarct size in dogs. Droxicainide decreases the sinus node, atrial and ventricular excitability and contractile force and increases the refractoriness in the study of spontaneously beating atria, electrically stimulated atria and papillary muscles isolated from rats.
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体ER
-
研究领域——
-
适应症——
化学信息
-
CAS Number78289-26-6
-
分子量276.38
-
分子式C16H24N2O2
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESCc1cccc(C)c1NC(=O)C1CCCCN1CCO
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Ohta, K., et al. Promising core structure for nuclear receptor ligands:Design and synthesis of novel estrogen receptor ligands based on diphenylamine skeleton. Bioorganic & Medicinal Chemistry Letters.2008;18(18), 5050–5053.
产品手册
关联产品
-
3,4-Dihydroxyphenyle...
3, 4-二羟基苯乙醇是从橄榄中提取的活性成分。
-
BRD0639
BRD0639 是一类抑制 PRMT5-substrate adaptor interaction 的抑制剂。BRD0639 是一种 PRMT5 结合基序 (PBM) 竞争剂，可以支持 PBM 依赖的 PRMT5 活性的研究。
-
Cyperotundone
Cyperotundone 是香附 (Cyperus rotundus) 的天然产物。
